• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Efficacy and Safety of Nonvitamin K Oral Anticoagulants in Patients with Atrial Fibrillation and Cancer: A Study-Level Meta-Analysis.
CONCLUSION:  In AF patients with malignancy, NOACs appear at least as effective as VKAs in preventing thrombotic events and reduce intracranial bleeding. NOACs may represent a valid and more practical alternative to VKAs in this setting of high-risk patients. PMID: 31785599 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 29, 2019 Category: Hematology Authors: Cavallari I, Verolino G, Romano S, Patti G Tags: Thromb Haemost Source Type: research

Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation.
In conclusion, in AF patients AF, VKA cessation is independently associated with mortality stroke and cardiovascular events. Specifically, VKA cessation independently increased the risk of stroke, even after adjusting for CHA2DS2-VASc score. TTR was an independent risk factor for major bleeding following initiation of VKA therapy. PMID: 24096615 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 7, 2013 Category: Hematology Authors: Gallego P, Roldan V, Marín F, Romera M, Valdés M, Vicente V, Lip GY Tags: Thromb Haemost Source Type: research

Comparing Mortality in Patients with Atrial Fibrillation who are Receiving a Direct Oral Anticoagulant or Warfarin: A Meta-analysis of Randomized Trials.
CONCLUSION: Compared with warfarin therapy for stroke prevention in patients with AF, DOACs significantly reduce all-cause mortality, vascular mortality and bleeding mortality. This mortality benefit appears to be driven by the reduction in vascular- and bleeding-related mortality which, in turn, may be related to the reduction in intracranial bleeding. This article is protected by copyright. All rights reserved. PMID: 24986568 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 1, 2014 Category: Hematology Authors: Liew A, O'Donnell M, Douketis J Tags: J Thromb Haemost Source Type: research

Acute hemorrhagic complications are associated with lower coated-platelet levels in non-lacunar brain infarction.
CONCLUSIONS: Lower levels of procoagulant platelets are associated with acute hemorrhagic complications following non-lacunar ischemic stroke. These results suggest a role for coated-platelets in risk/benefit assessment in the early stages of stroke. This article is protected by copyright. All rights reserved. PMID: 26426364 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 1, 2015 Category: Hematology Authors: Prodan CI, Stoner JA, Dale GL Tags: J Thromb Haemost Source Type: research

Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study.
CONCLUSIONS: Approximately 2 out of 10 hematological cancer patients experienced MI, ischemic stroke, VTE, or bleeding requiring hospital contact within 10 years. The hematological cancer cohort had higher hazards of MI, ischemic stroke, VTE, and bleeding requiring hospital contact than a general population comparison cohort. This article is protected by copyright. All rights reserved. PMID: 31054195 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - May 3, 2019 Category: Hematology Authors: Adelborg K, Corraini P, Darvalics B, Frederiksen H, Ording A, Horváth-Puhó E, Rørth M, Sørensen HT Tags: J Thromb Haemost Source Type: research

Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: Results from the GARFIELD-AF Registry
CONCLUSIONS: Patients who discontinued (n=3,114, 13.0%) had a higher risk (Hazard ratio [95% CI]) of all-cause death (1.62 [1.25-2.09]), stroke/systemic embolism (SE) (2.21 [1.42-3.44]) and myocardial infarction (MI) (1.85 [1.09-3.13]) than patients who did not, whether OAC was restarted or not. This higher risk of outcomes after discontinuation was similar for patients treated with vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) (p for interactions range=0.145-0.778). Bleeding history (1.43 [1.14-1.80]), paroxysmal vs. persistent AF (1.15 [1.02-1.29]), emergency room care setting vs. office (1.37 [1.18-...
Source: Thrombosis and Haemostasis - June 1, 2021 Category: Hematology Authors: Frank Cools Dana Johnson A John Camm Jean-Pierre Bassand Freek W A Verheugt Shu Yang Anastasios Tsiatis David A Fitzmaurice Samuel Z Goldhaber Gloria Kayani Shinya Goto Sylvia Haas Frank Misselwitz Alexander G G Turpie Keith A A Fox Karen S Pieper Ajay K Source Type: research

D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation - observations from the ARISTOTLE trial.
CONCLUSION: In anticoagulated patients with AF the level of D-dimer is related to the risk of stroke, death and bleeding and adds to the predictive value of clinical risk scores. The benefits of apixaban were consistent regardless of the baseline D-dimer level. This article is protected by copyright. All rights reserved. PMID: 24942912 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - June 18, 2014 Category: Hematology Authors: Christersson C, Wallentin L, Andersson U, Alexander JH, Ansell J, De Caterina R, Gersh BJ, Granger CB, Hanna M, Horowitz JD, Huber K, Husted S, Hylek EM, Lopes RD, Siegbahn A Tags: J Thromb Haemost Source Type: research

A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system.
In conclusion, compared with warfarin, dabigatran treatment was associated with a lower risk of stroke and most outcomes measured, but increased incidence of major lower GI bleeding. PMID: 26446456 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 8, 2015 Category: Hematology Authors: Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, Schwartzman E Tags: Thromb Haemost Source Type: research

D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy.
We examined baseline levels of D-dimer and their association with stroke, cardiovascular death and major bleeding in 6,202 AF patients randomised to dabigatran or warfarin in the RE-LY trial. The effects of treatment on serial levels of D-dimer and coagulation factor (F) VIIa in 2,567 patients were also analysed. Baseline D-dimer levels were related to the rate of stroke/systemic embolism (SEE) with 0.64 % in the lowest quartile (Q1, as reference) (D-dimer < 298 µg/l), 1.38 % Q2 (D-dimer 298-473 µg/l), 1.71 % Q3 (D-dimer 474-822 µg/l) and 2.00 % in Q4 (D-dimer > 822 µg/l) (p=0.0007). Similar associati...
Source: Thrombosis and Haemostasis - January 28, 2016 Category: Hematology Authors: Siegbahn A, Oldgren J, Andersson U, Ezekowitz MD, Reilly PA, Connolly SJ, Yusuf S, Wallentin L, Eikelboom JW Tags: Thromb Haemost Source Type: research

Anticoagulants Resumption after Warfarin-Related Intracerebral Haemorrhage: The Multicenter Study on Cerebral Hemorrhage in Italy (MUCH-Italy).
In conclusion, in patients who have an ICH while receiving warfarin, resuming anticoagulation results in a favorable trade-off between bleeding susceptibility and thromboembolic risk. PMID: 29433151 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - February 12, 2018 Category: Hematology Authors: Poli L, Grassi M, Zedde M, Marcheselli S, Silvestrelli G, Sessa M, Zini A, Paciaroni M, Azzini C, Gamba M, Toriello A, Tassi R, Giorli E, Calabrò RS, Ritelli M, De Vito A, Pugliese N, Martini G, Lanari A, Lodigiani C, Padroni M, De Giuli V, Caria F, Moro Tags: Thromb Haemost Source Type: research

Effectiveness and safety of apixaban vs. rivaroxaban in patients with atrial fibrillation and type 2 diabetes mellitus
CONCLUSIONS: Among patients with NVAF and T2DM, apixaban was associated with a similar risk of stroke, and a lower risk of major bleeding compared with rivaroxaban.PMID:35292949 | DOI:10.1055/a-1798-2116
Source: Thrombosis and Haemostasis - March 16, 2022 Category: Hematology Authors: Krishna Roy Chowdhury Jonathan Michaud Oriana Hoi Yun Yu Hui Yin Laurent Azoulay Christel Renoux Source Type: research

Adverse Events and All-Cause Mortality in Danish Patients with Cerebral Venous Thrombosis: A Nationwide Cohort Study
CONCLUSION: Intracranial bleeding, ischemic stroke, and mortality risks were higher for patients with CVT than matched patients with VTE and the general population, particularly within 6 months after diagnosis.PMID:35688451 | DOI:10.1055/s-0042-1743473
Source: Thrombosis and Haemostasis - June 10, 2022 Category: Hematology Authors: Anne Gulbech Ording Flemming Skj øth S øren Due Andersen Torben Bjerregaard Larsen Source Type: research

Pages: 1  2  3  4  5  6  7  8  9  10  11